Muctarr Sesay, PhD

Muctarr Sesay, Ph.D.

Chief Science Officer, Vice President Bioconjugation Development

Dr. Sesay has over 25 years of Biotechnology experience in biologics process development and manufacturing, bioconjugation and modification of biological molecules (including monoclonal and polyclonal antibodies, enzymes, toxins and others) and small molecules and over 17 years of experience in the Contract Development and Manufacturing (CDMO) sectors. Prior to joining Goodwin in 2002, Muctarr supervised many projects in R&D, Process Development and Manufacturing of biologics at Life Technologies Inc. (now Thermo Fischer), Kirkegaard and Perry Laboratories (KPL) and Elusys Therapeutics. Muctarr, after receiving his PhD in Biochemistry from the University of London (Queen Mary College), England worked for 3 years as a postdoctoral candidate at the University of Maryland, College Park in Protein Purification and characterization. In addition to his responsibilities at GBI, Dr. Sesay also is a member of the Advisory Committee for the Professional Science Master’s Degree in Medical Biotechnology offered by the College of Health Sciences at Barry University.